Immunowake
PrivateLast Round
Series A
May 15, 2022
Total Funding Raised
$23M
Company Overview
Immunowake, Inc. is a pre-clinical stage biotechnology company that develops bi-specific antibodies for cancer therapy. The company's mission is to create a universal cancer vaccine by developing safer and more effective therapeutics that can overcome immunosuppressive signals from tumors and activate the patient's immune system to recognize and kill cancer cells. Immunowake utilizes proprietary platforms, including a CD3 Bi-specific Platform and a VEGF Trap Platform, to design and screen multi-specific antibodies. The company has raised at least $23.5 million in funding, with a $20 million pre-Series A round in May 2022 intended to advance its cytokine pipeline through pre-IND studies and into Phase I clinical trials. The first IND application is anticipated by the end of 2025.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunowake Comps
Public and private peers based on sector, stage, and business model.
Immunowake Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 15, 2022 | ||||
| Seed | Aug 22, 2019 |
Immunowake Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heda Ventures | Series A |
| Lapam Capital | Series A |
| Hyfinity Investments | Series A |
Immunowake Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immunowake's valuation, stock price, and market status.
